AmSurg, LifePoint snag upgrades

Color John Ransom enthusiastic about AmSurg's game-changing play for Sheridan Healthcare. The veteran Raymond James analyst has upgraded shares of the ambulatory surgery company all the way to 'strong buy' from 'market perform' and sees the stock (Ticker: AMSG) rising to $60 from the $45.74 where it closed Thursday. Ransom also has raised his 2015 EPS estimate for AmSurg to $3.15 from $2.77.

Shares of LifePoint Hospitals hit an all-time high of $63.07 Friday morning thanks in part to an upgrade from Ann Hynes at Mizuho. Hynes now rates the hospital operator a 'buy' instead of a 'neutral' and has raised her target to $72 from $58. LifePoint shares (Ticker: LPNT) are up almost 2 percent to $61.99 in late-morning trading.